Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Income towards Parent Company (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Income towards Parent Company for 12 consecutive years, with -$108.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income towards Parent Company fell 10.17% year-over-year to -$108.2 million, compared with a TTM value of -$414.7 million through Dec 2025, down 162.0%, and an annual FY2025 reading of -$412.8 million, down 161.27% over the prior year.
  • Income towards Parent Company was -$108.2 million for Q4 2025 at Agios Pharmaceuticals, down from -$103.4 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at $2.0 billion in Q1 2021 and bottomed at -$112.5 million in Q2 2025.
  • Average Income towards Parent Company over 4 years is $116.2 million, with a median of -$88.0 million recorded in 2023.
  • The sharpest move saw Income towards Parent Company surged 4382.87% in 2021, then tumbled 110.91% in 2025.
  • Year by year, Income towards Parent Company stood at $4.0 million in 2021, then crashed by 2567.85% to -$97.7 million in 2023, then dropped by 0.53% to -$98.2 million in 2024, then fell by 10.17% to -$108.2 million in 2025.
  • Business Quant data shows Income towards Parent Company for AGIO at -$108.2 million in Q4 2025, -$103.4 million in Q3 2025, and -$112.5 million in Q2 2025.